Although the pathology of the respiratory system is the main impact of the COVID-19 disease, caused by the SARS-CoV-2 coronavirus, many of the patients manifest important neurological symptoms, such as loss of smell (anosmia), headaches, malaise, cognitive loss, epilepsy, ataxia, and encephalopathy, among others. However, this effect on the nervous system by the coronavirus has not been characterized in detail and it is unknown if the vaccines developed against COVID-19 prevent the spread of SARS-CoV-2 to the central nervous system and confer protection against brain injury. Now, using a mouse model susceptible to the SARS-CoV-2 coronavirus infection, a multidisciplinary team of Spanish researchers led by Dr. Javier Villadiego and Dr. Juan José Toledo-Aral (IBiS, CIBERNED and Department of Medical Physiology and Biophysics of the Faculty of Medicine of Seville), and Dr. Juan García-Arriaza (Department of Molecular and Cellular Biology of the CNB-CSIC, CIBERINFEC and PTI Global Health of CSIC), in collaboration with other groups from the University of Seville and the Spanish National Research Council (CSIC), demonstrate the ability of SARS-CoV-2 to infect different regions of the brain and to cause brain damage, and how the CNB-CSIC vaccine fully protects against infection of the brain. These findings were published on January 9, 2023 in Nature Neuroscience. The open-access article is titled “Full Protection from SARS-CoV-2 Brain Infection and Damage in Susceptible Transgenic Mice Conferred by MVA-CoV2-S Vaccine Candidate.”